



PRESS INFORMATION

FOR IMMEDIATE RELEASE



LAURUS SYNTHESIS INC. LAUNCHED AS U.S. AFFILIATE OF LAURUS LABS PVT, INDIA

Woburn, MA, January 28, 2015 – Dr. Satyanarayana Chava, Founder and CEO of Laurus Labs Private Limited, India, today announced that the company has launched Laurus Synthesis Inc., a new U.S. pharmaceutical and biotech services entity. Laurus Synthesis Inc. will operate under the leadership of two industry professionals, Stuart Needleman, named President, and Kevin Duffield, appointed Vice President, Operations. Both are recognized as highly experienced drug discovery and development experts.

Dr. Satyanarayana explained that the new company would begin operations immediately, providing U.S.- based clients with the full capabilities of Laurus Labs in India. Laurus Labs is one of India's top ten chemistry providers, offering process commercialization, process optimization and scale-up; manufacturing of API and drug product; and key starting materials (KSMs) and intermediates through its Laurus Synthesis business unit, which has been an integral part of Laurus Labs since the company's founding.

According to Mr. Chandrakanth Chereddi, Vice President in charge of the Laurus Synthesis business unit, "The launch of Laurus Synthesis Inc. represents an expansion into the U.S. market that will firmly accelerate growth by supporting clients locally and in India. With more than 100 scientists supporting Laurus Synthesis in India, the coordination of joint U.S. and India teams of experienced professionals will result in optimum speed and cost efficiency for clients."

In March of this year, Laurus Synthesis Inc. will begin offering their specialized laboratory services from a new, state-of-the-art drug development facility in Woburn, Massachusetts. From this site, clients will be assisted in advancing their concepts on the best path to their next milestone. Laurus Synthesis chemists and project managers will provide process development, method development and impurity identification services, as well as route selection for API, intermediates and starting materials. In addition, a smooth technical transition to the products and services of Laurus Labs for scale-up and commercialization will be available as required.

“We will support our new U.S. affiliate with our well established scientific team in Hyderabad, India, and our world class manufacturing facilities in Vizag, India,” said Dr. Satyanarayana. “Under Stu and Kevin’s exceptional leadership, a strong U.S.-based scientific and technical team is being assembled, specifically chosen for their record of innovating breakthrough chemistry. The result is that from Woburn, clients will have unparalleled front-end service for their chemistry needs and from our facilities in India, they benefit from world class back-end manufacturing resources.”

In conclusion, Dr. Satyanarayana stated that, “We stand ready to assist our clients through our resources in the U.S. and India. From east and west locations, an innovative approach in working with our customers and the integrity of our cultures prevail, allowing us to surpass our clients’ previous expectations of cost and time benefits with no compromise whatsoever in the quality of service and products that we provide.”

####

For more information or to arrange an interview, contact Maria Garvey at maria@delfino.com or 914.747.1400

####

About Laurus Labs Private Limited

Based in Visakhapatnam, India, Laurus Labs Private Limited (Laurus) develops and manufactures active pharmaceutical ingredients (API), with a focus on anti-retroviral (ARV) and oncology products. The company supplies its APIs to several Indian and global pharmaceutical companies. In addition to the API business, Laurus offers contract research (chemical, analytical and formulation development) and manufacturing services to generic and innovative pharmaceutical companies. Laurus has world-class infrastructure, consisting of a state-of-the-art R&D and scale-up laboratory in Hyderabad and large-scale manufacturing facilities at Visakhapatnam. These facilities have been accredited by several international regulatory agencies including the US-FDA, UK-MHRA, Australian TGA and Korean FDA. The company has revenues approaching \$250 million and currently employs 1,800+ people. For more information, please visit www.lauruslabs.com